Phase I/II Trial of Sorafenib (Nexavar) and RAD001 (Everolimus) in the Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma.

Trial Profile

Phase I/II Trial of Sorafenib (Nexavar) and RAD001 (Everolimus) in the Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 May 2014

At a glance

  • Drugs Everolimus (Primary) ; Sorafenib
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 12 Jun 2012 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 04 Jan 2012 Planned end date changed from 1 Jun 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 13 Sep 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top